Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group B fHbp recombinant vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK3536852A is a recombinant protein vaccine candidate developed by GSK for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroup B. It consists of two recombinant factor H binding protein (fHbp) variants, one from each of the two major subfamilies (A and B). This bivalent fHbp approach is intended to provide broad protection against diverse MenB strains by inducing serum bactericidal antibodies that block the function of fHbp, a surface protein that allows the bacteria to evade the host's immune system by binding human factor H. While GSK already markets a multicomponent MenB vaccine (Bexsero), GSK3536852A was specifically developed to be the serogroup B component of GSK's pentavalent MenABCWY vaccine candidate, as its formulation is more compatible with the capsular polysaccharide conjugate components of Menveo than the multicomponent Bexsero formulation.
- Other names
- Meningococcal group B fHbp recombinant vaccineBivalent r-fHbp vaccine
02
Targets
NadA (Neisserial adhesin A)fHbp (Factor H-binding protein)PorANHBA (Neisserial heparin-binding antigen)
Beyond the preview
Go deeper on meningococcal group B fHbp recombinant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group B fHbp recombinant vaccine.